IFIH1-mediated Post-transcriptional Regulation of PTTG1 Promotes Proliferation and Affects PHA-848125 Sensitivity and Prognosis in Oropharyngeal Carcinoma

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Jun 11

PMID 38859832

Authors

Xiaoli Li

Nan Ding

Wenting Ma

Ming Zhang

Affiliations

Soon will be listed here.

Abstract

The pituitary tumor-transforming gene 1 (PTTG1) is an oncogene involved in chromosomal segregation, DNA repair, apoptosis, and metabolism. PTTG1 can be used for clinical diagnosis and treatment and is a potential target for oropharyngeal carcinoma. The proliferation and viability of Cal27 and FaDu cells were assessed using the CCK-8 assay. Real-time PCR and western blotting, respectively, were used to analyze the mRNA and protein expression levels of PTTG1 and IFIH1. The interaction between mRNA and the translational regulatory protein IFIH1 was analyzed using RNA pull-down, RNA immunoprecipitation, and luciferase reporter assays. PTTG1 protein was significantly overexpressed in oropharyngeal carcinoma, whereas mRNA was not. We hypothesized that a translation regulatory protein plays a post-transcriptional role in PTTG1. The IFIH1 protein specifically bound to the 42-52 nt region of mRNA, promoted the translation of PTTG1, and promoted the proliferation of oropharyngeal cancer cells. Administration of the PTTG1 inhibitor PHA-848125 and silencing of IFIH1 synergistically decreased the expression of PTTG1, inhibited the proliferation of oropharyngeal cancer cells, and indicated a good prognosis. We found that the IFIH1-PTTG1 axis could regulate the PHA-848125 response and functionally mediate inter-individual oropharyngeal cancer susceptibility and prognosis. This study aimed to confirm the upstream regulatory genes of PTTG1 and further investigate the specific interactions in this signaling pathway, which will provide a new approach for the treatment of oropharyngeal carcinoma.

References

Yao L, Cong R, Ji C, Zhou X, Luan J, Meng X . RNA-Binding Proteins Play an Important Role in the Prognosis of Patients With Testicular Germ Cell Tumor. Front Genet. 2021; 12:610291. PMC: 7990889. DOI: 10.3389/fgene.2021.610291. View

Dias Junior A, Sampaio N, Rehwinkel J . A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. Trends Microbiol. 2018; 27(1):75-85. PMC: 6319154. DOI: 10.1016/j.tim.2018.08.007. View

Fischer H, Tschachler E, Eckhart L . Pangolins Lack IFIH1/MDA5, a Cytoplasmic RNA Sensor That Initiates Innate Immune Defense Upon Coronavirus Infection. Front Immunol. 2020; 11:939. PMC: 7225364. DOI: 10.3389/fimmu.2020.00939. View

Gurvits N, Repo H, Loyttyniemi E, Nykanen M, Anttinen J, Kuopio T . Prognostic implications of securin expression and sub-cellular localization in human breast cancer. Cell Oncol (Dordr). 2016; 39(4):319-31. DOI: 10.1007/s13402-016-0277-5. View

Panguluri S, Yeakel C, Kakar S . PTTG: an important target gene for ovarian cancer therapy. J Ovarian Res. 2008; 1(1):6. PMC: 2584053. DOI: 10.1186/1757-2215-1-6. View

Bernal J, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F . Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet. 2002; 32(2):306-11. DOI: 10.1038/ng997. View

Maier T, Guell M, Serrano L . Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009; 583(24):3966-73. DOI: 10.1016/j.febslet.2009.10.036. View

Manyes L, Holst S, Lozano M, Santos E, Fernandez-Medarde A . Spatial learning and long-term memory impairments in RasGrf1 KO, Pttg1 KO, and double KO mice. Brain Behav. 2018; 8(11):e01089. PMC: 6236249. DOI: 10.1002/brb3.1089. View

Khazaei G, Shamsabadi F, Yamchi A, Golalipour M, Jhingan G, Shahbazi M . Proteomics evaluation of MDA-MB-231 breast cancer cells in response to RNAi-induced silencing of hPTTG. Life Sci. 2019; 239:116873. DOI: 10.1016/j.lfs.2019.116873. View

10.

Chen P, Yen J, Kao R, Chen J . Down-regulation of the oncogene PTTG1 via the KLF6 tumor suppressor during induction of myeloid differentiation. PLoS One. 2013; 8(8):e71282. PMC: 3745464. DOI: 10.1371/journal.pone.0071282. View

11.

Degrassi A, Russo M, Nanni C, Patton V, Alzani R, Giusti A . Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther. 2010; 9(3):673-81. DOI: 10.1158/1535-7163.MCT-09-0726. View

12.

Chao J, Liu H . The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol Pharmacol. 2005; 69(1):154-64. DOI: 10.1124/mol.105.015503. View

13.

Wu M, Ma Q, Liu D, Li X, Deng L, Li N . CDC20 and its downstream genes: potential prognosis factors of osteosarcoma. Int J Clin Oncol. 2019; 24(11):1479-1489. DOI: 10.1007/s10147-019-01500-3. View

14.

Kim C, Ying H, Willingham M, Cheng S . The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis. 2006; 28(5):932-9. DOI: 10.1093/carcin/bgl231. View

15.

Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca M . Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther. 2010; 9(8):2243-54. DOI: 10.1158/1535-7163.MCT-10-0190. View

16.

Minematsu T, Miyai S, Kajiya H, Suzuki M, Sanno N, Takekoshi S . Recent progress in studies of pituitary tumor pathogenesis. Endocrine. 2005; 28(1):37-41. DOI: 10.1385/ENDO:28:1:037. View

17.

Ma K, Sun X, Ma L, Zhang S . Expression of Serum PTTG1 in Laryngeal Carcinoma and Its Correlation to Prognosis. Clin Exp Otorhinolaryngol. 2019; 13(1):64-68. PMC: 7010490. DOI: 10.21053/ceo.2019.00395. View

18.

Cho-Rok J, Yoo J, Jang Y, Kim S, Chu I, Yeom Y . Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2006; 43(5):1042-52. DOI: 10.1002/hep.21137. View

19.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

20.

Caporali S, Alvino E, Levati L, Esposito A, Ciomei M, Brasca M . Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochem Pharmacol. 2012; 84(5):598-611. DOI: 10.1016/j.bcp.2012.06.004. View